A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection
一种针对铜绿假单胞菌感染的新型粘膜疫苗
基本信息
- 批准号:10550157
- 负责人:
- 金额:$ 19.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute respiratory infectionAcute suppurative arthritis due to bacteriaAdjuvantAge YearsAnaerobic BacteriaAntibiotic ResistanceAntibioticsAntibodiesAntibody ResponseAntibody titer measurementAntigensAntimicrobial ResistanceBacteremiaBacteriaCancer PatientCapsid ProteinsCellsCellular ImmunityChronicClassificationCollaborationsCombined AntibioticsCommunicable DiseasesContact LensesCritical IllnessDefectDevelopmentDiseaseDoseEnzymesExotoxinsEye InfectionsFolliculitisGoalsHIVHealth care facilityHealthcareHumanHumoral ImmunitiesImmuneImmune responseImmunityImmunizationImmunizeImmunologistImplantIndividualInfectionIntranasal AdministrationKeratitisLinkLong-Term Care for ElderlyLung infectionsMalignant NeoplasmsMediatingMeningitisMicrobial BiofilmsMilitary PersonnelModelingMorbidity - disease rateMucosal ImmunityMucous MembraneMulti-Drug ResistanceMusNatureOperative Surgical ProceduresOrgan TransplantationOsteomyelitisOtitis ExternaPatientsPhagocytosisPharmaceutical PreparationsPilot ProjectsPlantsPneumoniaPneumonic PlaguePreventionProtein SubunitsPseudomonasPseudomonas aeruginosaPseudomonas aeruginosa infectionPseudomonas aeruginosa pneumoniaPublic HealthRecombinant ProteinsRecurrenceResearchResearch PersonnelResistance to infectionRespiratory MucosaRespiratory SystemRespiratory Tract InfectionsRiskSchemeSepsisSerotypingSkin TissueSoft Tissue InfectionsSoldierSubunit VaccinesSurfaceSurgical Wound InfectionSystemSystemic infectionT cell responseT-LymphocyteTestingTobacco Mosaic VirusTobacco useToxoidsTransplant RecipientsTreatment ProtocolsUrinary tract infectionVaccinationVaccine AntigenVaccinesVirulence FactorsWorld Health OrganizationWound InfectionYersinia pestisbaseburn woundcatheter associated UTIcolistin resistancecombat woundcystic fibrosis infectioncystic fibrosis patientsear infectioneffective therapyefflux pumpexperiencefirst responderhealthcare-associated infectionshigh riskhigh risk populationhuman pathogenimmunogenicitymodel organismmortalitymouse modelmucosal vaccinationmucosal vaccinemultidrug-resistant Pseudomonas aeruginosanovelolder patientopportunistic pathogenpathogenpreclinical developmentpreventprotective efficacyprototyperesistance mechanismresistant strainresponsesevere burnsvaccine developmentvaccine efficacyvaccine immunogenicityventilator-associated pneumonia
项目摘要
Project Summary
Pseudomonas aeruginosa (PA) is an opportunistic pathogen that causes a diverse array of disease
manifestations. It is a major cause of healthcare associated infections worldwide, chronic lung infection in
patients with cystic fibrosis (CF), and burn wound infections. There is a high rate of antimicrobial resistance in
PA, leading to significant morbidity and mortality from infection. The World Health Organization has classified
multidrug resistant (MDR) PA as a priority 1 pathogen for research. As infections with MDR strains of PA have
become commonplace, treatment options have become limited. We propose to develop a vaccine to prevent PA
infection in high-risk individuals. Prior attempts to develop a PA vaccine have focused on protection from
respiratory infection, most notably ventilator-associated pneumonia and lung infection in CF patients. These
attempts have been unsuccessful despite the induction of detectable vaccine-specific antibody responses in
immunized patients. We and others hypothesize that the parenteral immunization scheme and adjuvants used
in these studies do not produce the full spectrum of balanced humoral and cellular immunity necessary for
effective protection from PA in the respiratory tract. This can be overcome through direct immunization at the
mucosal surface with an adjuvant that can induce Th17 immunity, as Th17 immunity has been shown to be a
critical component for protection to PA. Furthermore, vaccines administered at mucosal surfaces have also been
shown to generate protective systemic immune responses. We are developing a vaccine that can be
administered mucosally, providing complete protection not only against respiratory infection with PA, but also
against non-mucosal disease manifestations; thus, providing complete immunity to the pathogen. The vaccine
will consist of a minimum of four virulence factors to provide broad protection against the large number of PA
serotypes present in nature. In this application, we will evaluate PcrV, OprF, OprI, and Exotoxin A toxoid as
vaccine targets. These antigens will be conjugated to Tobacco Mosaic Virus, which we have previously
demonstrated to be an effective delivery platform for the mucosal delivery of subunit vaccine antigens. In a pilot
study, we demonstrated that IN delivery of TMV-PcrV protected 66% of mice from lethal challenge with 10xLD50
of PA in an acute lung infection model, whereas all uninfected mice succumbed to infection. In the present study
we will optimize vaccine immunogenicity for each of the four TMV conjugates, evaluating functional antibody and
T cell responses following IN vaccination, and testing protective efficacy in an acute lung infection model of PA.
We will then test the ability of a combined multivalent vaccine against five different strains of PA using both the
lung infection model, and a foreign implant biofilm model. Using this we will establish proof of principle for our
approach and develop a prototype vaccine to move into preclinical development in a subsequent R01 application.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul Michael Arnaboldi其他文献
Paul Michael Arnaboldi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul Michael Arnaboldi', 18)}}的其他基金
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection
一种针对铜绿假单胞菌感染的新型粘膜疫苗
- 批准号:
10446501 - 财政年份:2022
- 资助金额:
$ 19.59万 - 项目类别:
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
基于肽的即时垂直流检测用于快速诊断莱姆病
- 批准号:
10404209 - 财政年份:2020
- 资助金额:
$ 19.59万 - 项目类别:
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
基于肽的即时垂直流检测用于快速诊断莱姆病
- 批准号:
10452660 - 财政年份:2020
- 资助金额:
$ 19.59万 - 项目类别:
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
基于肽的即时垂直流检测用于快速诊断莱姆病
- 批准号:
10080510 - 财政年份:2020
- 资助金额:
$ 19.59万 - 项目类别:
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
基于肽的即时垂直流检测用于快速诊断莱姆病
- 批准号:
10653862 - 财政年份:2020
- 资助金额:
$ 19.59万 - 项目类别:
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
基于肽的即时垂直流检测用于快速诊断莱姆病
- 批准号:
10668819 - 财政年份:2020
- 资助金额:
$ 19.59万 - 项目类别:
An antigen-capture assay to screen donated blood for Babesia microti
用于筛查捐献血液中是否含有田鼠巴贝虫的抗原捕获测定
- 批准号:
9893818 - 财政年份:2019
- 资助金额:
$ 19.59万 - 项目类别:
A Rapid Point-of-Care Assay for the Diagnosis of Lyme Disease
诊断莱姆病的快速护理点检测
- 批准号:
9135755 - 财政年份:2016
- 资助金额:
$ 19.59万 - 项目类别:
Peptide-based Multiplex Assay for Lyme disease Serodiagnosis
基于肽的莱姆病血清学诊断多重检测
- 批准号:
9045060 - 财政年份:2016
- 资助金额:
$ 19.59万 - 项目类别:
Development of a Cytokine Release Assay as a Diagnostic Test for Lyme Disease
开发细胞因子释放测定作为莱姆病的诊断测试
- 批准号:
8393091 - 财政年份:2012
- 资助金额:
$ 19.59万 - 项目类别:
相似海外基金
2022 Biology of Acute Respiratory Infection GRC / GRS
2022 急性呼吸道感染生物学 GRC / GRS
- 批准号:
10388659 - 财政年份:2022
- 资助金额:
$ 19.59万 - 项目类别:
The Canadian Severe Acute Respiratory Infection, Prospective, Perpetual Observational Study: Informing Clinical Care and the Public Health Response
加拿大严重急性呼吸道感染前瞻性、永久性观察研究:为临床护理和公共卫生应对提供信息
- 批准号:
462643 - 财政年份:2022
- 资助金额:
$ 19.59万 - 项目类别:
Operating Grants
The Canadian Severe Acute Respiratory Infection, Prospective, Perpetual Observational Study: Informing Clinical Care and the Public Health Response
加拿大严重急性呼吸道感染前瞻性、永久性观察研究:为临床护理和公共卫生应对提供信息
- 批准号:
442907 - 财政年份:2020
- 资助金额:
$ 19.59万 - 项目类别:
Operating Grants
2020 Biology of Acute Respiratory Infection Gordon Research Conference and Gordon Research Seminar
2020急性呼吸道感染生物学戈登研究大会暨戈登研究研讨会
- 批准号:
9913675 - 财政年份:2020
- 资助金额:
$ 19.59万 - 项目类别:
New test for the diagnosis of acute respiratory infection that detects viruses and evaluates host gene expression in a nasal sample
用于诊断急性呼吸道感染的新测试,可检测鼻腔样本中的病毒并评估宿主基因表达
- 批准号:
9809720 - 财政年份:2019
- 资助金额:
$ 19.59万 - 项目类别:
2016 Biology of Acute Respiratory Infection Gordon Research Conference & Gordon Research Seminar
2016年急性呼吸道感染生物学戈登研究会议
- 批准号:
9121654 - 财政年份:2016
- 资助金额:
$ 19.59万 - 项目类别:
2014 Biology of Acute Respiratory Infection Gordon Research Conference and Semina
2014年急性呼吸道感染生物学戈登研究会议及研讨会
- 批准号:
8650427 - 财政年份:2014
- 资助金额:
$ 19.59万 - 项目类别:
Meditation and Exercise for Preventing Acute Respiratory Infection (MEPARI-2)
预防急性呼吸道感染的冥想和运动(MEPARI-2)
- 批准号:
8867144 - 财政年份:2012
- 资助金额:
$ 19.59万 - 项目类别:
Meditation and Exercise for Preventing Acute Respiratory Infection (MEPARI-2)
预防急性呼吸道感染的冥想和运动(MEPARI-2)
- 批准号:
9098602 - 财政年份:2012
- 资助金额:
$ 19.59万 - 项目类别:
2012 Biology of Acute Respiratory Infection Gordon Research Conference
2012年急性呼吸道感染生物学戈登研究会议
- 批准号:
8249190 - 财政年份:2012
- 资助金额:
$ 19.59万 - 项目类别:














{{item.name}}会员




